Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Diagnosis of CD30-positive peripheral T-cell lymphoma, including anaplastic large cell lymphoma (ALK-positive, ALK-negative, breast implant-associated), peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma.
Patients 18 years of age or older at the time of treatment with BV-CHP.
Patients treated with brentuximab vedotin plus CHP as first-line therapy between January 2019 and September 2024

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain